Skip to main content Accessibility help
×
Hostname: page-component-78c5997874-s2hrs Total loading time: 0 Render date: 2024-11-03T09:05:23.006Z Has data issue: false hasContentIssue false

31 - The role of ß-amyloid in Alzheimer's disease

from Part IV - Alzheimer's disease

Published online by Cambridge University Press:  04 August 2010

M. Flint Beal
Affiliation:
Cornell University, New York
Anthony E. Lang
Affiliation:
University of Toronto
Albert C. Ludolph
Affiliation:
Universität Ulm, Germany
Roger M. Nitsch
Affiliation:
Division of Psychiatry Research, University of Zurich, August Forel Strasse 1, Zurich 8008, Switzerland
Get access

Summary

Introduction

ß-Amyloid is a central element of the histopathology of Alzheimer's disease. It damages neurons and it causes the formation of neurofibrillary tangles. It is genetically linked to mutations that cause familial Alzheimer's disease, and it is associated with polymorphisms that increase the risk for developing Alzheimer's disease. ß-Amyloid can be imaged by positron emission tomography in living people, and it is a major therapeutic target for the development of disease-modifying therapies (Selkoe, 2004).

ß-amyloid plaques are major histophathological hallmarks of Alzheimer's disease

The neuropathological diagnosis of Alzheimer's disease is based upon the presence in brain of ß-amyloid plaques and neurofibrillary tangles (Duyckaerts & Dickson, 2003). ß-Amyloid deposits occur within the neuropil in several forms depending upon the degree of aggregation and fibrillization of the amyloid ß-peptides Aß40 and Aß42, their principal proteinaceous components. The two most abundant, albeit different, forms of amyloid plaques are neuritic ß-amyloid plaques and diffuse plaques. Neuritic, or “senile,” ß-amyloid plaques occur rarely in healthy subjects, they are an early histopathological sign of Alzheimer's disease (Tiraboschi et al., 2004). Neuritic ß-amyloid plaques are composed of higher-order ß-amyloid fibrils that can be detected by Thioflavin S or Congo red, as well as by silver-based stains and by immunohistochemistry. Amyloid fibrils within the cores of neuritic ß-amyloid plaques visualized by electron microscopy have diameters of upto 10 nm, and often occur in radiating, star-like assemblies.

Type
Chapter
Information
Neurodegenerative Diseases
Neurobiology, Pathogenesis and Therapeutics
, pp. 452 - 458
Publisher: Cambridge University Press
Print publication year: 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aguzzi, A. & Haass, C. (2003). Games played by rogue proteins in prion disorders and Alzheimer's disease. Science, 302, 814–18CrossRefGoogle ScholarPubMed
Aisen, P. S., Mehran, M., Poole, R.et al. (2004). Clinical data on Alzhemed™ after 12 months of treatment in patients with mild to moderate Alzheimer's disease. Neurobiol. Agin., 25S2, 20 (abstract)CrossRefGoogle Scholar
Bard, F., Cannon, C., Barbour, R. et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6, 916–19CrossRefGoogle Scholar
Bennett, D. A., Schneider, J. A., Wilson, R. S., Bienias, J. L. & Arnold, S. E. (2004). Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. Arch. Neurol., 61, 378–84CrossRefGoogle ScholarPubMed
Chapman, P. F., White, G. L., Jones, M. W.et al. (1999). Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci., 2, 271–6CrossRefGoogle ScholarPubMed
Delaere, P., Duyckaerts, C., He, Y., Piette, F. & Hauw, J. J. (1991). Subtypes and differential laminar distributions of beta A4 deposits in Alzheimer's disease: relationship with the intellectual status of 26 cases. Acta Neuropathol., 81, 328–35CrossRefGoogle ScholarPubMed
Delaere, P., He, Y., Fayet, G., Duyckaerts, C. & Hauw, J. J. (1993). Beta A4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol. Agin., 14, 191–4CrossRefGoogle ScholarPubMed
Dudal, S., Krzywkowski, P., Paquette, J. et al. (2004). , P, Gervais, F. Inflammation occurs early during the Abeta deposition process in TgCRND8 mice. Neurobiol. Agin., 25, 861–71CrossRefGoogle ScholarPubMed
Duyckaerts, C. & Dickson, D. W. (2003). Neuropathology in Alzheimer's disease. In Neurodegeneration. The Molecular Pathology of Dementia and Movement Disorders, ed. Dickson Basel: ISN Neuropath Press. pp. 47–65
Ferrari, A., Hoerndli, F., Baechi, T., Nitsch, R. M. & Götz, J. (2003). Beta-amyloid induces PHF-like tau filaments in tissue culture. J. Biol. Chem., 278, 40162–8CrossRefGoogle ScholarPubMed
Ferrer, I., Boada Rovira, M., Sanchez Guerra, M. L., Rey, M. J. & Costa-Jussa, F. (2004). Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol., 14, 11–20CrossRefGoogle ScholarPubMed
Fox, N. C., Black, R. S., Gilman, S.et al. (2004). Effects of a-beta immunotherapy (AN1792) on MRI measures of brain, ventricle and hippocampal volumes in Alzheimer's disease. NeuroBiol. Agin., 25S2, 84CrossRefGoogle Scholar
Giasson, B. I., Lee, V. M. & Trojanowski, J. Q. (2003). Interactions of amyloidogenic proteins. Neuromolec. Med., 49–58CrossRefGoogle ScholarPubMed
Gilman, S., Koller, M., Black, R. S.et al. (2004). Neuropsychological, CSF, and neuropathological effects of a-beta immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol. Agin., 25S2, 84 (abstract)CrossRefGoogle Scholar
Götz, J., Chen, F., Dorpe, J. & Nitsch, R. M. (2001). Abeta42 fibrils induce the formation of neurofibrillary tangles in P301L tau transgenic mice. Science, 293, 1491–5CrossRefGoogle Scholar
Greeve, I., Kretzschmar, D., Beyn, A. et al. (2004). Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci., 24, 3899–906CrossRefGoogle ScholarPubMed
Hock, C., Konietzko, U., Papassotiropoulos, A. et al. (2002). Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat. Med., 8, 1270–5CrossRefGoogle ScholarPubMed
Hock, C., Konietzko, U., Streffer, J. R.et al. (2003). Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron, 38, 547–54CrossRefGoogle ScholarPubMed
Ingelsson, M., Fukumoto, H., Newell, K. L.et al. (2004). Early A-beta accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain. Neurology, 62, 925–31CrossRefGoogle Scholar
Klunk, W. E., Engler, H., Nordberg, A. et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol., 55, 306–19CrossRefGoogle ScholarPubMed
Knopman, D. S., Parisi, J. E., Salviati, A. et al. (2003). Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol., 62, 1087–95CrossRefGoogle ScholarPubMed
Koo, E. H. & Kopan, R. (2004). Potential role of presenilin-regulated signaling pathways in sporadic neurodegeneration. Nat. Med., 10 Suppl:S26–33CrossRef
Lemere, C. A., Beierschmitt, A., Iglesias, M. et al. (2004). Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet. Am. J. Pathol., 165, 283–97CrossRefGoogle Scholar
Lewis, J., Dickson, D. W., Lin, W. L.et al. (2001). Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science, 293, 1487–91CrossRefGoogle ScholarPubMed
Lombardo, J. A., Stern, E. A., McLellan, M. E.et al. (2003). Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci., 23, 10879–83CrossRefGoogle ScholarPubMed
Marjaux, E., Hartmann, D. & Strooper, B. (2004). Presenilins in memory, Alzheimer's disease, and therapy. Neuron, 42(2), 189–92CrossRefGoogle ScholarPubMed
Mattson, M. P. (2004). Pathways towards and away from Alzheimer's disease. Nature, 430, 631–9CrossRefGoogle ScholarPubMed
Mattson, M. P. & Chan, S. L. (2003). Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium, 34, 385–97CrossRefGoogle ScholarPubMed
Mohajeri, H. M., Saini, K., Schultz, J. G., Wollmer, M. A., Hock, C. & Nitsch, R. M. (2002). Passive immunization against β-amyloid peptide protects CNS neurons from increased vulnerability associated with an Alzheimer's disease-causing mutationJ. Biol. Chem., 277, 33012–17CrossRefGoogle ScholarPubMed
Morgan, D., Diamond, D. M., Gottschall, P. E.et al. (2000). A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature, 408, 982–5CrossRefGoogle Scholar
Nicoll, J. A., Wilkinson, D., Holmes, C., Steart, P., Markham, H. & Weller, R. O. (2003). Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med., 9, 448–52CrossRefGoogle ScholarPubMed
Nicoll, J. A., Yamada, M., Frackowiak, J., Mazur-Kolecka, B. & Weller, R. O. (2004). Cerebral amyloid angiopathy plays a direct role in the pathogenesis of Alzheimer's disease. Pro-CAA position statement. Neurobiol. Agin., 25, 589–97CrossRefGoogle Scholar
Nitsch, R. M., Slack, B. E., Wurtman, R. J. & Growdon, J. H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science, 258, 304–7CrossRefGoogle ScholarPubMed
Nitsch, R. M., Deng, M., Tennis, M., Schoenfeld, D. & Growdon, J. H. (2000). The selective muscarinic M1 agonist AF102B decreases levels of total Abeta in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol., 48, 913–183.0.CO;2-S>CrossRefGoogle ScholarPubMed
Oddo, S., Caccamo, A., Shepherd, J. D.et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron, 39, 409–21CrossRefGoogle ScholarPubMed
Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H. & LaFerla, F. M. (2004). Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43, 321–32CrossRefGoogle Scholar
Ritchie, C. W., Bush, A. I., Mackinnon, A. et al. (2003). Metal–protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol., 60, 1685–91CrossRefGoogle ScholarPubMed
Rossjohn, J., Cappai, R., Feil, S. C.et al. (1999). Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol., 6(4), 327–31Google ScholarPubMed
Sano, M., Ernesto, C., Thomas, R. G.et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 336, 1216–22CrossRefGoogle ScholarPubMed
Schenk, D., Barbour, R., Dunn, W. et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173–7CrossRefGoogle ScholarPubMed
Selkoe, D. J. (2004). Alzheimer disease: mechanistic understanding predicts novel therapies. Ann. Intern. Med., 140, 627–38CrossRefGoogle ScholarPubMed
Selkoe, D. & Kopan, R. (2003). Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. Annu. Rev. Neurosci., 26, 565–97CrossRefGoogle ScholarPubMed
Stern, E. A., Bacskai, B. J., Hickey, G. A., Attenello, F. J., Lombardo, J. A. & Hyman, B. T. (2004). Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J. Neurosci., 24, 4535–40CrossRefGoogle ScholarPubMed
Tanzi, R. E. & Bertram, L. (2001). New frontiers in Alzheimer's disease genetics. Neuron, 32, 181–4CrossRefGoogle ScholarPubMed
Tiraboschi, P., Hansen, L. A., Thal, L. J. & Corey-Bloom, J. (2004). The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 62, 1984–9CrossRefGoogle ScholarPubMed
Gool, W. A., Aisen, P. S. & Eikelenboom, P. (2003). Anti-inflammatory therapy in Alzheimer's disease: is hope still alive?J. Neurol., 250, 788–92CrossRefGoogle ScholarPubMed
Rotz, R. C., Kohli, B. M., Bosset, J.et al. (2004). The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor. J. Cell Sci., 117, 4435–48CrossRefGoogle Scholar
Walsh, D. M., Klyubin, I., Fadeeva, J. V.et al. (2002). Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature, 416, 535–9CrossRefGoogle ScholarPubMed
Wilcock, D. M., Rojiani, A., Rosenthal, A. et al. (2004). Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J. Neurosci., 24, 6144–51CrossRefGoogle Scholar
Zandi, P. P., Anthony, J. C., Khachaturian, A. S.et al. (2004). Cache County Study Group. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch. Neurol., 61, 82–8CrossRefGoogle Scholar

Save book to Kindle

To save this book to your Kindle, first ensure [email protected] is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×